STOCK TITAN

Personalis to Announce First Quarter 2022 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Personalis, Inc. (NASDAQ: PSNL) will release its Q1 2022 financial results on May 4, 2022, at 2:00 p.m. PT. Following the release, a conference call will occur to discuss financial results and highlights. Interested participants can join via phone or through a live webcast on the company's website.

Personalis specializes in advanced genomics for cancer treatments, utilizing the Personalis NeXT Platform to provide comprehensive genetic insights from single samples, enhancing precision cancer therapies.

Positive
  • None.
Negative
  • None.

MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (866) 220-8061 for domestic callers or (470) 495-9168 for international callers, using conference ID: 3187833. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

About Personalis

Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter.

Investor Relations Contact for Personalis:

Caroline Corner

investors@personalis.com

www.westwicke.com

415-202-5678

Media Contact for Personalis:

Jennifer Temple

pr@personalis.com

www.personalis.com

650-752-1300

Source: Personalis, Inc.

FAQ

When will Personalis report its Q1 2022 financial results?

Personalis will report its Q1 2022 financial results on May 4, 2022.

What time is the Personalis conference call on May 4, 2022?

The conference call is scheduled for 2:00 p.m. Pacific Time.

How can I access the Personalis Q1 2022 earnings call?

The earnings call can be accessed via telephone or through a live webcast on the Personalis website.

What platform does Personalis use for cancer genomics?

Personalis uses the Personalis NeXT Platform for advanced cancer genomics.

What is the focus of Personalis, Inc.?

Personalis focuses on advanced genomics to enable precision cancer therapies and diagnostics.

Personalis, Inc.

NASDAQ:PSNL

PSNL Rankings

PSNL Latest News

PSNL Stock Data

474.58M
54.05M
19.3%
53.16%
4.04%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FREMONT